Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis

NCT ID: NCT04636684

Last Updated: 2024-10-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-01
• Study Completion Date: 2025-12-31

Brief Summary

Cardiac amyloidosis is a restrictive cardiomyopathy with a potentially severe prognosis that can be life-threatening. It is linked in the vast majority of cases to a light chain deposition of immunoglobulin or transthyretin. Although myocardial involvement is predominant, other locations are possible: the atrioventricular conduction system, coronary arteries and valve leaflets. In systematic histological analyzes, deposits of amyloidosis infiltrating the aortic valve have been reported with a frequency of up to 74% for degenerative RA. The nature of these deposits has never been established because the immunostaining carried out all remained negative, probably due to decalcification prior to cutting. Currently, these deposits are considered to be local degenerative phenomena without clinical repercussions. However, the use of bone scintigraphy has shown a high prevalence, between 14 and 16%, of ATTR cardiac amyloidosis in patients with severe RA. The diagnosis of ATTR amyloidosis has been proven histologically in a few patients. Sequencing of the TTR gene has shown that they are mainly wild forms. In fact, the prevalence of transthyretin mutations in our local cohort is 20%.

The objective of this study is to determine by proteomic analysis based on mass spectrometry, the prevalence of ATTR aortic valve amyloidosis in patients undergoing surgical valve replacement for degenerative aortic stenosis.

Conditions

Amyloidosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

patients undergoing surgical valve replacement for degenerative aortic stenosis

Group Type: EXPERIMENTAL

Proteomic analysis

Intervention Type: DIAGNOSTIC_TEST

Proteomic analysis based on mass spectrometry on the sample of valve tissues.

Interventions

Proteomic analysis

Proteomic analysis based on mass spectrometry on the sample of valve tissues.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Patient over 18 years old
• Degenerative aortic stenosis
• Aortic valve replacement surgery
• Signature of the informed consent form

Exclusion Criteria

• Non-degenerative aortic stenosis: bicuspid, rheumatic disease, aortic regurgitation
• Persons under a system of legal protection for adults (guardianship, curatorship, etc.)
• Pregnant women

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Toulouse

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Magali COLOMBAT, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

university hospital center Toulouse

Toulouse, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Magali COLOMBAT, MD

Role: CONTACT

colombat.m@chu-toulouse.fr

5 31 15 61 40 ext. +33

Olivier LAIREZ, MD

Role: CONTACT

lairez.o@chu-toulouse.fr

5 61 32 28 73 ext. +33

Facility Contacts

Audrey TOMASIK

Role: primary

tomasik.a@chu-toulouse.fr

5 61 77 85 97 ext. +33

Other Identifiers

RC31/19/0446

Identifier Type: -

Identifier Source: org_study_id